Positive
"The expectation for this study, based on our prior clinical experience, is that HA-Irinotecan will provide improved clinical benefit to patients without increasing the burden of toxicity. While it is still early in the trial, the data presented to the DSMB is consistent with that expectation.”
Negative
slow recruitment
ha-irinotecan phase 3 trial update , page-3
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable